Suppr超能文献

摩洛哥一组感染艾滋病毒儿童的乙肝疫苗接种反应评估。

Assessment of the HBV vaccine response in a group of HIV-infected children in Morocco.

作者信息

Haban Houda, Benchekroun Soumia, Sadeq Mina, Benjouad Abdelaziz, Amzazi Said, Oumzil Hicham, Elharti Elmir

机构信息

National Reference Laboratory for HIV, Department of Virology, National Institute of Hygiene, Rabat, Morocco.

Immunology-Biochemistry Laboratory, Faculty of Sciences, University Mohammed Vth, Rabat, Morocco.

出版信息

BMC Public Health. 2017 Sep 29;17(1):752. doi: 10.1186/s12889-017-4776-8.

Abstract

BACKGROUND

Since its development in the early 1980s, Hepatitis B virus (HBV) vaccine has been proven to be highly protective. However, its immunogenicity may be ineffective among HIV-infected children. In Morocco, HBV vaccine was introduced in 1999, and since then all infants, including vertically HIV-infected infants, have been following the vaccination schedule, implemented by the Moroccan ministry of health. An assessment of the immunization of these children is important to optimize efforts aimed at tackling Hepatitis B coinfection, within the country.

METHODS

Forty-nine HIV-infected children (HIV group) and 112 HIV uninfected children (control group) were enrolled in this study. Samples were tested by Elisa (Monolisa Anti-HBs, Biorad) to quantify the anti-HBs antibodies. The % of lymphocyte subsets i.e. CD4+ T cells, CD8+ T cells, B cells, and NK, was determined by flow cytometry, using CellQuest Pro software (Becton-Dickinson), and for HIV group, HIV viral load was measured by real time PCR assay (Abbott). All variables were statistically compared in the two groups.

RESULTS

The median age was 51 ± 35 months for the HIV group and 50 ± 36 months (p > 0.05) for the control group. Female represented 63% and 41% (p = 0.01), among the HIV group and the control group, respectively. Among HIV-infected children, 71.4% (35/49) were under HAART therapy at the enrollment in the study. Seroprotection titer i.e. anti-HBs ≥10mUI/ml among control group was 76% (85/112), and only 29% (14/49) among the perinatally HIV-infected children (p < 0.0001). Lower % of CD4 + T cells was observed in HIV-infected children with a poor anti-HBs response.

CONCLUSION

In this studied group, we have shown that despite the vaccination of HIV-children with HBV vaccine, 71% did not show any seroprotective response. These findings support the need for monitoring HBV vaccine response among HIV-infected children in Morocco, in order to revaccinate non-immunized children.

摘要

背景

自20世纪80年代初研发以来,乙肝病毒(HBV)疫苗已被证明具有高度保护作用。然而,其免疫原性在感染HIV的儿童中可能无效。在摩洛哥,1999年引入了HBV疫苗,从那时起,所有婴儿,包括垂直感染HIV的婴儿,都按照摩洛哥卫生部实施的疫苗接种计划进行接种。评估这些儿童的免疫情况对于优化该国应对乙肝合并感染的努力非常重要。

方法

本研究纳入了49名感染HIV的儿童(HIV组)和112名未感染HIV的儿童(对照组)。通过酶联免疫吸附测定法(Monolisa Anti-HBs,伯乐公司)检测样本,以定量抗-HBs抗体。使用CellQuest Pro软件(贝克顿-迪金森公司)通过流式细胞术测定淋巴细胞亚群(即CD4 + T细胞、CD8 + T细胞、B细胞和NK细胞)的百分比,对于HIV组,通过实时聚合酶链反应测定法(雅培公司)测量HIV病毒载量。对两组中的所有变量进行统计学比较。

结果

HIV组的中位年龄为51±35个月,对照组为50±36个月(p>0.05)。HIV组和对照组中女性分别占63%和41%(p = 0.01)。在感染HIV的儿童中,71.4%(35/49)在研究入组时接受高效抗逆转录病毒治疗(HAART)。对照组中抗-HBs≥10mUI/ml的血清保护滴度为76%(85/112),而在围产期感染HIV的儿童中仅为29%(14/49)(p<0.0001)。在抗-HBs反应不佳的感染HIV的儿童中观察到较低的CD4 + T细胞百分比。

结论

在该研究组中,我们表明尽管感染HIV的儿童接种了HBV疫苗,但71%的儿童未表现出任何血清保护反应。这些发现支持在摩洛哥监测感染HIV的儿童对HBV疫苗的反应的必要性,以便对未免疫的儿童进行重新接种。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5159/5622525/b1cdc7184898/12889_2017_4776_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验